ArticleGastroenterology research and practice2009
Short bowel patients treated for two years with glucagon-like Peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function.
Article in Gastroenterology research and practice, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02889393 (Teduglutide for Treatment of Enterocutaneous Fistula), which is not on this map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Teduglutide for Treatment of Enterocutaneous Fistula (ECF) - a Pilot Study to Demonstrate Safety and Feasibility
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 99 citations in OpenAlex.
- Current practice and future perspectives in the treatment of short bowel syndrome in children--a systematic review.Langenbeck's archives of surgery · 2012Pooled it
- Pooled it
- Apraglutide, a novel once-weekly glucagon-like peptide-2 analog, improves intestinal fluid and energy absorption in patients with short bowel syndrome: An open-label phase 1 and 2 metabolic balance trial.JPEN. Journal of parenteral and enteral nutrition · 2022Trial
- Apraglutide, a novel glucagon-like peptide-2 analog, improves fluid absorption in patients with short bowel syndrome intestinal failure: Findings from a placebo-controlled, randomized phase 2 trial.JPEN. Journal of parenteral and enteral nutrition · 2022Trial
- Glucagon-like peptide-2 regulates release of chylomicrons from the intestine.Gastroenterology · 2014Trial
- Randomised controlled trial of colostrum to improve intestinal function in patients with short bowel syndrome.European journal of clinical nutrition · 2012Trial
- Trial
- Chronic, but not acute, treatment with GLP-2 and GIP in combination increases glucose absorption in the isolated vascularly perfused rat intestine.Physiological reports · 2026Article
- GLP-2 and GIP acutely increase superior mesenteric artery blood flow in male rats, and the effect is independent of nitric oxide and vasoactive intestinal peptide.Physiological reports · 2025Article
- Role of Peptides in Skeletal Muscle Wasting: A Scoping Review.Journal of cachexia, sarcopenia and muscle · 2025Article
- Chronic Intestinal Failure and Short Bowel Syndrome in Adults: The State of the Art.GE Portuguese journal of gastroenterology · 2024Review
- Home Parenteral Support in Chronic Intestinal Failure-First Results from a Pioneer Portuguese Intestinal Failure Center.Nutrients · 2024Article
- Gut hormones and bone homeostasis: potential therapeutic implications.Nature reviews. Endocrinology · 2024Review
- GLP-2 regulation of intestinal lipid handling.Frontiers in physiology · 2024Review
- Long-Term Intestinal Failure and Home Parenteral Support: A Single Center Experience.GE Portuguese journal of gastroenterology · 2023Article
- Article
- An updated overview of glucagon-like peptide-2 analog trophic therapy for short bowel syndrome in adults.The Journal of international medical research · 2022Review
- Proglucagon-Derived Peptides as Therapeutics.Frontiers in endocrinology · 2021Review
- Effect of enzymatic hydrolysate of cottonseed protein supplementation on growth performance and intestinal health of nursery pigs in Thailand.Tropical animal health and production · 2020Article
- The Long Road to the Development of Effective Therapies for the Short Gut Syndrome: A Personal Perspective.Digestive diseases and sciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsIn a short-term study, Glucagon-like peptide 2 (GLP-2) has been shown to improve intestinal absorption in short bowel syndrome (SBS) patients. This study describes longitudinal changes in relation to GLP-2 treatment for two years.
methodsGLP-2, 400 micrograms, s.c.,TID, were offered, to eleven SBS patients keeping parenteral support constant. 72-hour nutritional balance studies were performed at baseline, weeks 13, 26, 52 during two years intermitted by an 8-week washout period. In addition, mucosal morphometrics, renal function (by creatinine clearance), body composition and bone mineral density (by DEXA), biochemical markers of bone turnover (by s-CTX and osteocalcin, PTH and vitamin D), and muscle function (NMR, lungfunction, exercise test) were measured.
resultsGLP-2 compliance was >93%. Three of eleven patients did not complete the study. In the remaining 8 patients, GLP-2 significantly reduced the fecal wet weight from approximately 3.0 to approximately 2.0 kg/day. This was accompanied by a decline in the oral wet weight intake, maintaining intestinal wet weight absorption and urinary weight constant. Renal function improved. No significant changes were demonstrated in energy intake or absorption, and GLP-2 did not significantly affect mucosal morphology, body composition, bone mineral density or muscle function.
conclusionsGLP-2 treatment reduces fecal weight by approximately 1000 g/d and enables SBS patients to maintain their intestinal fluid and electrolyte absorption at lower oral intakes. This was accompanied by a 28% improvement in creatinine clearance.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.